Ryoncil (remestemcel‑L‑rknd) for steroid‑refractory acute graft‑versus‑host disease
Customize your policy alerts
Sign up for Blue Cross Blue Shield - Iowa Policy 05.05.89 alerts
Get alerted when Policy 05.05.89 changes without checking for updates manually.
Monitor payer policy activity
This policy describes benefit application, coverage criteria, and billing for Ryoncil (remestemcel‑L‑rknd) for treatment of steroid‑refractory acute graft‑versus‑host disease (SR‑aGvHD) in pediatric patients, and applies to members covered under Blue Cross Blue Shield - Iowa contracts.
No material clinical or coverage changes in this revision.
Coverage Criteria for Ryoncil (remestemcel‑L‑rknd)
Initial therapy (acute GvHD)
Covered when ALL of the following are met
Pediatric ≥ 2 months per FDA indication
Continuation / Reauthorization
Reauthorization/continued treatment — authorization may be granted when either of the following is met
Ryoncil (remestemcel‑L‑rknd) is considered not medically necessary for members who do not meet the coverage criteria set forth above.
Use of Ryoncil for indications or patient populations not meeting the specified criteria is considered not medically necessary.
Candidate Population
Transplant population
Candidate population for therapy
Matches FDA indication
Provider Actions, Documentation & Billing
Prior authorization and reporting codes for Ryoncil
Prior authorization may be granted for Ryoncil (remestemcel‑L‑rknd) for steroid‑refractory acute graft‑versus‑host disease in pediatric patients who meet the coverage criteria. Report services using the listed HCPCS/CPT or unclassified biologic codes as appropriate (see coding section).
- Authorization may be granted for up to 2 months (maximum 8 infusions) for initial therapy.
- Reauthorization limits: partial/mixed response — maximum 4 infusions; recurrence after complete response — maximum 8 infusions.
Corticosteroid requirement (steroid‑refractory definition)
Authorization requires prior adequate systemic corticosteroid therapy, defined as methylprednisolone 2 mg/kg/day (or equivalent), with steroid‑refractory disease defined as progression within 3 days or no improvement within 7 consecutive days of that corticosteroid therapy.
- Steroid‑refractory timing: progressed within 3 days OR did not improve within 7 consecutive days of methylprednisolone 2 mg/kg/day (or equivalent).
Benefits verification and potential dosing limits
Verify member benefits and contract exclusions before requesting authorization, as benefits may vary by contract; approvals may be subject to dosing limits per FDA labeling, accepted compendia, or evidence‑based guidelines.
- Confirm the member has applicable benefit coverage and no contract exclusions.
- Expect possible dosing limits consistent with FDA‑approved labeling and accepted references.
Not medically necessary if coverage criteria are not met
Use of Ryoncil is considered not medically necessary for members who do not meet the coverage criteria set forth in this policy.
- Do not submit authorization requests for indications or patient populations that do not meet the specified criteria; such use is not medically necessary.
Billing and Coding
Post‑Transplant Coverage Details
Definitions
Evaluation Requirements and Documentation
Evaluation requirements — document prior corticosteroid therapy and timing
Documentation must include evidence of prior adequate corticosteroid therapy (methylprednisolone 2 mg/kg/day or equivalent) and timing consistent with the steroid‑refractory definition to support authorization.
- Record the corticosteroid dose, start date, and clinical course demonstrating progression within 3 days or lack of improvement within 7 consecutive days.
- Include clinical notes showing pediatric age and applicable infusion counts if requesting continuation or reauthorization.
Background
Ryoncil (remestemcel‑L‑rknd) is indicated for the treatment of steroid‑refractory acute graft‑versus‑host disease (SR‑aGvHD) in pediatric patients aged 2 months and older. Authorization for initial therapy may be granted for up to 2 months (maximum of 8 infusions), with reauthorization limited by response criteria (partial response: maximum of 4 infusions; recurrence after complete response: up to a maximum of 8 infusions).
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.